This work was partly supported by grants from the Uehara Memorial Foundation and Takeda Science Foundation
Semaglutide is an efficient once-weekly treatment alternative for the Chinese population with T2D
Diabetes 58: 1604-1615, 2009
Always inform your healthcare provider about all prescription, over-the-counter medications, and supplements you use
It's an investigational drug currently in Phase 3 clinical trials Eli Lilly's TRIUMPH Phase 3 program includes multiple trials for obesity, type 2 diabetes, NASH, and cardiovascular outcomes Expected timeline: FDA submission in 2026, potential approval in 20272028 Phase 2 results showed 24.2% weight loss at 48 weeks, the highest ever recorded for a GLP-1 class medication How to access now: Clinical trial enrollment (free), compounding pharmacies (with important legal caveats), or research peptides (grey market) When approved, retatrutide will be the first triple-agonist obesity medication (GLP-1 + GIP + glucagon) Is Retatrutide FDA Approved
